Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
-
Child's play for Haaland as Man City star strikes again
-
India crush Pakistan by 88 runs amid handshake snub, umpiring drama
-
Hojlund fires Napoli past Genoa and into Serie A lead
-
Sevilla rout 'horrendous' Barca in Liga thrashing
-
Haaland fires Man City to win at Brentford, Everton end Palace's unbeaten run
-
Haaland extends hot streak as Man City sink Brentford
-
Italy working hard to prevent extra US tariffs on pasta
-
Sinner out of Shanghai Masters as Djokovic battles into last 16
-
Swift rules N. America box office with 'Showgirl' event
-
Ryder Cup hero MacIntyre wins Alfred Dunhill Links on home soil
-
Republicans warn of pain ahead as US shutdown faces second week
-
Sevilla rout champions Barca in shock Liga thrashing
-
Norris-Piastri clash overshadows McLaren constructors' title win
-
Trump administration declares US cities war zones
-
Bad Bunny takes aim at Super Bowl backlash in 'SNL' host gig
-
El Khannouss fires Stuttgart into Bundesliga top four
-
Insatiable Pogacar romps to European title
-
Newcastle inflict more pain on Postecoglou, Everton end Palace's unbeaten run
-
Daryz wins emotional and thrilling Prix de l'Arc de Triomphe
-
US Open finalist Anisimova wins Beijing title in 'great year'
-
Daryz wins Prix de l'Arc de Triomphe thriller
-
Russell wins Singapore GP as McLaren seal constructors' title
-
Landslides and floods kill 64 in Nepal, India
-
Russell wins Singapore GP, McLaren seal constructors' title
-
Djokovic 'hangs by rope' before battling into Shanghai last 16
-
Erasmus proud of Boks' title triumph as Rugby Championship faces uncertain future
-
US Open finalist Anisimova caps breakthrough year with Beijing title
-
French PM under pressure to put together cabinet
-
US Open finalist Anisimova beats Noskova to win Beijing title
-
Hamas calls for swift hostage-prisoner swap as talks set to begin
-
Opec+ plus to raise oil production by 137,000 barrels a day in November
-
Death toll from Indonesia school collapse rises to 45
-
Brisbane Broncos edge Storm in thrilling NRL grand final
-
Hamas calls for swift prisoner release as talks set to begin
-
Refreshed Sabalenka 'ready to go' after post-US Open break
-
Marquez fears 'something is broken' as world champion hurt in crash
-
Georgia PM vows sweeping crackdown after 'foiled coup'
-
Landslides and floods kill 63 in Nepal, India
-
No handshakes again as India, Pakistan meet at Women's World Cup
-
Georgia PM announces sweeping crackdown on opposition after 'foiled coup'
-
Syria selects members of first post-Assad parliament
-
Russian strikes kill five in Ukraine, cause power outages
-
World champion Marquez crashes out as Aldeguer wins Indonesia MotoGP.
-
World champion Marquez crashes out of Indonesia MotoGP
-
Babis to meet Czech president after party tops parliamentary vote
-
Death toll from Indonesia school collapse rises to 37
-
OPEC+ meets with future oil production hanging in the balance
-
Dodgers down Phillies on Hernandez homer in MLB playoff series opener
-
Philadelphia down NYCFC to clinch MLS Supporters Shield
-
Syria selects members of first post-Assad parliament in contested process
NYSE - LSE
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
DENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2025 full year and fourth quarter, after the market close on Tuesday, September 23, 2025. The Company has scheduled a conference call and webcast that same day, Tuesday, September 23, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Tuesday, September 23, 2025, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 447137.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/52803, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until October 7, 2025, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 52803.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
A.Jones--AMWN